NEPH Stock Analysis: Buy, Sell, or Hold?
NEPH - Nephros Inc.
$4.31
-0.08 (-1.82%)
▼
5d:
-7.91%
30d:
-8.69%
90d:
-20.92%
HOLD
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 23, 2026
Get Alerted When NEPH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NEPH shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: NEPH shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: NEPH is currently trading at $4.31, which is considered oversold relative to its 30-day fair value range of $4.43 to $4.97. The stock's valuation (Forward PE: 28.7) is in line with its historical norms (31.9). Remarkably, the market is currently pricing in an annual earnings decline of 3.5% over the next few years. This pessimistic expectation contrasts with the company's recent 72.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, NEPH is showing sideways momentum. The price is currently testing key support at $4.28. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NEPH has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $7.00 (+62.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NEPH is showing sideways momentum. The price is currently testing key support at $4.28. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NEPH has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $7.00 (+62.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$4.43 -
$4.97
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 62.4% below Wall St target ($7.00)
- CAUTION: 5-day price weakness (-7.9%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$4.43 -
$4.97
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$4.28
Resistance Level
$5.09
Current Trend
Sideways
Fundamental Context
Forward P/E (Next Year Est.)
28.73
Wall Street Target
$7.00
(+62.4%)
Revenue Growth (YoY)
35.4%
Earnings Growth (YoY)
72.9%
Profit Margin
8.3%
Valuation Discount vs History
-3.5% cheaper
PE vs Historical
28.7 vs 31.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.5%
(market-implied from PE analysis)
1-Year Target
$4.16
(-4%)
2-Year Target
$4.01
(-7%)
3-Year Target
$3.87
(-10%)
3-Yr Target (if PE normalizes)
(PE: 29→32)
$4.30
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 28.7, Growth: 36.4%)
$10.93
(+154%)
Base:
(SPY PE: 22.3, Growth: 36.4%)
$8.48
(+97%)
Bear:
(PE: 19.0, Growth: 36.4%)
$7.21
(+67%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (32x PE), but valuation improves significantly next year (29x PE) as earnings recover.
Trailing PE: 32.21 | Current EPS (TTM): $0.14
Bull Case
$5.32
(+23%)
Analyst growth 7.1%, PE expands to 35.4
Base Case
$4.83
(+12%)
Market implied 7.1%, PE stable at 32.2
Bear Case
$3.07
(-29%)
Severe decline -20.0%, PE contracts to 27.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 28.7 to 31.9
Stabilization Target:
$4.78
(+11.0%)
PE Expansion Potential:
+11.0%
Last updated: February 01, 2026 9:19 PM ET
Data refreshes hourly during market hours. Next update: 10:19 PM
Data refreshes hourly during market hours. Next update: 10:19 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NEPH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$92 | 63 BUY |
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$612 | 58 HOLD |
|
RGEN
Repligen Corporation |
STRONG BUY
19 analysts |
$191 | 58 HOLD |
|
RMD
ResMed Inc |
BUY
19 analysts |
$297 | 57 HOLD |
|
ALGN
Align Technology Inc |
BUY
18 analysts |
$184 | 62 BUY |
